» Articles » PMID: 38987656

Characterization of a Missense Variant in COG5 in a Tunisian Patient with COG5-CDG Syndrome and Insights into the Effect of Non-synonymous Variants on COG5 Protein

Abstract

The clinical diagnosis of patients with multisystem involvement including a pronounced neurologic damage is challenging. High-throughput sequencing methods remains crucial to provide an accurate diagnosis. In this study, we reported a Tunisian patient manifesting hypotonia and global developmental delay with visual and skin abnormalities. Exome sequencing was conducted followed by segregation analysis and, subsequently additional investigations. In silico analysis of non-synonymous variants (nsSNPs) described in COG5 in conserved positions was made. Results revealed a homozygous missense variant c.298 C > T (p.Leu100Phe) in the COG5 inherited from both parents. This variant altered both protein solubility and stability, in addition to a putative disruption of the COG5-COG7 interaction. This disruption has been confirmed using patient-derived cells in vitro in a COG5 co-immuno-precipitation, where interaction with binding partner COG7 was abrogated. Hence, we established the COG5-CDG diagnosis. Clinically, the patient shared common features with the already described cases with the report of the ichtyosis as a new manifestation. Conversely, the CADD scoring revealed 19 putatively pathogenic nsSNPs (Minor Allele Frequency MAF < 0.001, CADD > 30), 11 of which had a significant impact on the solubility and/or stability of COG5. These properties seem to be disrupted by six of the seven missense COG5-CDG variants. In conclusion, our study expands the genetic and phenotypic spectrum of COG5-CDG disease and highlight the utility of the next generation sequencing as a powerful tool in accurate diagnosis. Our results shed light on a likely molecular mechanism underlying the pathogenic effect of missense COG5 variants, which is the alteration of COG5 stability and solubility.

References
1.
Jaeken J, Matthijs G . Congenital disorders of glycosylation: a rapidly expanding disease family. Annu Rev Genomics Hum Genet. 2007; 8:261-78. DOI: 10.1146/annurev.genom.8.080706.092327. View

2.
Jaeken J, Hennet T, Matthijs G, Freeze H . CDG nomenclature: time for a change!. Biochim Biophys Acta. 2009; 1792(9):825-6. PMC: 3917312. DOI: 10.1016/j.bbadis.2009.08.005. View

3.
Pokrovskaya I, Willett R, Smith R, Morelle W, Kudlyk T, Lupashin V . Conserved oligomeric Golgi complex specifically regulates the maintenance of Golgi glycosylation machinery. Glycobiology. 2011; 21(12):1554-69. PMC: 3219415. DOI: 10.1093/glycob/cwr028. View

4.
Gonzalez-Dominguez C, Raya-Trigueros A, Manrique-Hernandez S, Gonzalez Jaimes A, Salinas-Marin R, Molina-Garay C . Identification through exome sequencing of the first PMM2-CDG individual of Mexican mestizo origin. Mol Genet Metab Rep. 2020; 25:100637. PMC: 7451422. DOI: 10.1016/j.ymgmr.2020.100637. View

5.
Matthijs G, Rymen D, Bistue Millon M, Souche E, Race V . Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG. Glycoconj J. 2012; 30(1):67-76. DOI: 10.1007/s10719-012-9445-7. View